Navigation Links
Boehringer Ingelheim Presents New Phase II Data for Volasertib in Adult Patients with AML
Date:12/10/2012

).

Boehringer Ingelheim intends to begin recruitment of a Phase III study (NCT01721876) to assess the efficacy and safety of volasertib in combination with LDAC compared with LDAC alone in early 2013.  The planned Phase III trial, POLO-AML-2, will enroll eligible patients aged 65 or older with previously untreated AML who are ineligible for intensive remission induction therapy.6  For additional information on the trial, please visit ClinicalTrials.gov.

About Volasertib
Volasertib, an investigational inhibitor of polo-like kinase (Plk), is one of several late-stage compounds that Boehringer Ingelheim is currently evaluating in clinical trials for various solid tumors and hematological cancers.

Of the company's ongoing research in cell cycle inhibition, the volasertib clinical development program is the furthest advanced. Boehringer Ingelheim is one of the first companies to advance Plk inhibitors into clinical development.

Volasertib is designed to inhibit the activity of Plk1, an enzyme that regulates cell division (mitosis).  This inhibition is intended to result in prolonged cell cycle arrest and ultimately cell death (apoptosis).7

Volasertib is not approved by the FDA; its safety and efficacy have not been established.

About Acute Myeloid Leukemia (AML)
AML is a cancer of the bone marrow and the blood.8  It is one of the most common types of leukemia in adults, accounting for 25 percent of all adult leukemias in the Western world,9 and has one of the lowest survival rates of all leukemias.2

AML is primarily a disease of later adulthood; the average age of an AML patient is 65 years.10  In patients diagnosed with AML at age 65 or older, the prognosis is poor.5

About Boehringer Ingelh
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Boehringer Ingelheim Announces Equine Research Awards
2. Phase 2b Data of Boehringer Ingelheims Interferon-Free Hepatitis C Treatment Show Viral Cure Achieved in Up to 85% of Treatment-Naive Patients
3. Whistleblowers extraordinary efforts helped win $95 million settlement with Boehringer Ingelheim
4. Boehringer Ingelheim announces afatinib expanded access program (EAP) for patients with EGFR mutation-positive advanced NSCLC
5. Boehringer Ingelheim and Lilly introduce the My Well Planner Lifestyle Improvement Program for Adults with Type 2 Diabetes
6. Lilly and Boehringer Ingelheim Present Data at the 72nd American Diabetes Association Scientific Sessions® from Phase II Studies Comparing Investigational Novel Basal Insulin to Insulin Glargine
7. Boehringer Ingelheim Presents First Data for Tiotropium in Adolescents with Moderate Persistent Asthma
8. Results of Phase II Study of Boehringer Ingelheims Investigational Bronchodilator for COPD Presented at 2012 ATS International Conference
9. Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012
10. New Data to be Presented at the Annual American Thoracic Society International Conference Demonstrates Depth of Boehringer Ingelheim Respiratory Research Pipeline
11. Boehringer Ingelheim Announces Launch of GLORIA™-AF Registry in Newly-Diagnosed Patients with Non-Valvular Atrial Fibrillation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... ROCKY HILL, Conn. , July 29, 2014 ... 28, 2014, Mike Swinford will be the company,s ... after a highly successful 22-year career at GE where he ... $200 million in annual revenue to over $5 billion. His ... Healthcare Global Services. "I am thrilled to ...
(Date:7/29/2014)... 29, 2014 McGraw-Hill Education Professional, a leading ... technical, and medical communities, has announced the launch of ... application of the world-renowned medical education platform. ... App , available for download onto all iOS and ... to gain access to valuable AccessMedicine diagnostic ...
(Date:7/29/2014)... 2014  Neurocrine Biosciences, Inc. (Nasdaq: NBIX ... second quarter 2014 financial results after the Nasdaq market ... host a live conference call and webcast to discuss ... morning, August 7, 2014 at 8:00 a.m. Eastern Time ... the live conference call by dialing 866-952-1907 (US) or ...
Breaking Medicine Technology:Numotion Names Mike Swinford CEO 2McGraw-Hill Education Professional's AccessMedicine App Delivers Instant Access to Essential Diagnostic Tools 2McGraw-Hill Education Professional's AccessMedicine App Delivers Instant Access to Essential Diagnostic Tools 3Neurocrine Biosciences Announces Conference Call And Webcast To Report Second Quarter 2014 Financial Results 2
(Date:7/29/2014)... Colorado (PRWEB) July 29, 2014 The ... Gossip reveals the inside story to Gary M. Levin’s ... a remarkable cure method for this serious disorder. Levin ... most discouraging conditions that can be found in patients. ... MD and surgeon. For many years, Levin has worked ...
(Date:7/29/2014)... Winter is here down under, and ... Sydney’s central business district. That is, until a troop ... the otherwise ordinary day into a celebration—a celebration of ... advocates of The Truth About Drugs, a drug prevention ... They woke up the city with a rousing performance ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 Daily Gossip reveals ... 5 step holistic system that will permanently eliminate all the ... Coleman his natural treatment will banish symptoms such as mild ... beeping sound heard by patients will be gone forever. , ... 60 days. The author of this program says that at ...
(Date:7/29/2014)... TUESDAY, July 29, 2014 (HealthDay News) --,The time at ... affect their chances for survival, new research suggests. ... weekends or during holidays is associated with a 13 ... business hours, researchers report. Every year, more than ... most severe type of heart attack, which is caused ...
(Date:7/29/2014)... the bite of a brown recluse spider is poisonous, ... expert notes. It,s still important to recognize the ... recluse spider bite, warned Dr. Donna Seger, medical director ... dangerous bites are on the rise. "As physicians, ... [bite] has classic characteristics, but if physicians are not ...
Breaking Medicine News(10 mins):Health News:Natural Multiple Sclerosis Treatment Review Reveals the Inside Story to Gary M. Levin’s Cure Program 2Health News:Sydney Business District “Rocked” by The Truth About Drugs 2Health News:Tinnitus Miracle Review Exposes the Only Holistic System for Tinnitus Cure 2Health News:Heart Attack Patients Treated at Night, Weekends May Have Worse Outcomes 2Health News:Brown Recluse Spider Bites on the Rise, Expert Warns 2
... Aeras and the China National Biotech Group (CNBG) today ... organizations to pursue opportunities to jointly develop tuberculosis (TB) vaccines ... The partnership is intended to leverage both organizations, capabilities ... a major public health priority in China, where there are ...
... Serena Gordon HealthDay Reporter , MONDAY, July 25 (HealthDay ... worry to add to their list: Kids younger than 10 years ... on their own. New research found that while children ... the street solo -- they do stop and look both ways ...
... specific genes shuts down the mass production of antibodies launched ... by scientists at The University of Texas MD Anderson Cancer ... "Regulatory T cells prevent unwanted or exaggerated immune system ... been unclear," said paper senior author Chen Dong, Ph.D., professor ...
... ALBUQUERQUE, N.M. Americans are used to drinking from ... water utilities might be vulnerable to terrorist attacks or ... an open-source software developed by Sandia National Laboratories ... public water systems can be protected through enhanced detection ...
... , MONDAY, July 25 (HealthDay News) -- As ... school this fall, the American Lung Association urged parents to ... and help ease their transition back to the classroom. ... back-to-school necessities, it is even more essential for parents of ...
... of oncologists in the Program in Women,s Oncology at Women ... guide to the human papilloma virus (HPV) so physicians can ... women with the virus. Dx/Rx: Human Papilloma Virus was ... oncology at Women & Infants and associate professor of obstetrics ...
Cached Medicine News:Health News:Aeras and China National Biotech Group sign memorandum of understanding for TB vaccine R&D 2Health News:Kids With ADHD Less Adept at Crossing the Street: Study 2Health News:Kids With ADHD Less Adept at Crossing the Street: Study 3Health News:Specialized regulatory T cell stifles antibody production centers 2Health News:Specialized regulatory T cell stifles antibody production centers 3Health News:Sandia's CANARY software protects water utilities from terrorist attacks and contaminants 2Health News:Sandia's CANARY software protects water utilities from terrorist attacks and contaminants 3Health News:Preparation Key When Kids With Asthma Go Back to School 2Health News:Oncologists publish HPV manual for physicians 2
... The product is intended for ... spine following anterior fusion. The device ... addition, load sharing is enhanced through ... thickness. Anterior cervical single level interbody ...
... the newest addition to the ... plates. Ant-Cer addresses the unique ... the cervical spine. It enables ... to fit patients' unique needs. ...
... plate system is a family of plates ... provides for consistent, reliable fixation of plate ... or backout. This innovative design eliminates the ... implant your screws and the swivel ring ...
Investigational use spacer with Cantilever Transforminal Lumbar Interbody Fusion and instrumentation. For Investigational use only. 7 mm height....
Medicine Products: